Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 14/20 | 0.51 |
| ▸ | TP53 | P04637 | 9/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988496 | 0.90 | SERPINE1 (0.71) | SERPINE1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL2994026 | 0.89 | SERPINE1 (0.64) | SERPINE1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL2987383 | 0.85 | SERPINE1 (0.65) | SERPINE1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL12091650 | 0.85 | SERPINE1 (0.65) | SERPINE1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL2985685 | 0.84 | SERPINE1 (0.69) | SERPINE1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL2991523 | 0.82 | SERPINE1 (0.64) | SERPINE1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL1221052 | 0.81 | LMNA (0.74) | MAPTTP53LMNASMN1; SMN2THRB | |
| SCHEMBL2996651 | 0.81 | SERPINE1 (0.69) | SERPINE1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL2993861 | 0.81 | SERPINE1 (0.62) | SERPINE1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL2987677 | 0.79 | SERPINE1 (0.63) | SERPINE1MAPTTP53LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| CN-101460164-A | Compounds for diseases and disorders | MYRIAD GENETICS INC (US) | 2009-06-17 | — | — | CN | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2010187-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| CN-101068781-A | Compounds for alzheimer's disease | MYRIAD GENETICS INC (US) | 2007-11-07 | — | — | CN | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1809601-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006041874-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | SERPINE1 4871/4885MAPT 657/4885TP53 3208/4885 |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | SERPINE1 4871/4885MAPT 657/4885TP53 3208/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | SERPINE1 4873/4885MAPT 46/4885TP53 306/4885 |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | PSEN2, PSEN1, CLN6 | SERPINE1 4847/4885MAPT 28/4885TP53 253/4885 |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | PSEN2, CHAT, PSEN1 | SERPINE1 4841/4885MAPT 24/4885TP53 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.